Lv1
30 积分 2023-08-03 加入
药源性肾损害的诊治与预防
12小时前
已完结
An evaluation of elranatamab for the treatment of myeloma: current evidence for treating relapsed/refractory disease and future directions
19天前
已完结
[Guidelines for the diagnosis and management of multiple myeloma in China (2024 revision)]
19天前
已完结
Ruxolitinib after fedratinib failure in patients with myelofibrosis: A real‐world case series
1个月前
已完结
Indication and management of allogeneic haematopoietic stem-cell transplantation in myelofibrosis: updated recommendations by the EBMT/ELN International Working Group
2个月前
已完结
Managing side effects of JAK inhibitors for myelofibrosis in clinical practice
3个月前
已完结
A first-in-class JAK/ROCK inhibitor, Rovadicitinib in patients with myelofibrosis who were refractory or relapsed or intolerant to Ruxolitinib: A single-arm, multicenter, open-label, phase Ib study
3个月前
已完结
Emerging Therapeutic Approaches for Anemia in Myelofibrosis
5个月前
已完结
A first-in-class JAK/ROCK inhibitor, Rovadicitinib in patients with myelofibrosis who were refractory or relapsed or intolerant to Ruxolitinib: A single-arm, multicenter, open-label, phase Ib study
6个月前
已完结
Myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis: Ringing in a new future
9个月前
已完结
皖公网安备34019202002308
